Ir para o conteúdo principal

Sight Sciences (NASDAQ: SGHT) — Perfil da empresa, notícias e dados financeiros

Logo de Sight Sciences
SGHT Sight Sciences
Sight Sciences primary media
Perfil da empresa

Sight Sciences

Sight Sciences (NASDAQ:SGHT) is a medical device company focused on developing innovative products that address unmet needs in the treatment of eye diseases and conditions. Their portfolio mainly revolves around technologies aimed at improving the outcomes of patients suffering from glaucoma and dry eye disease. By investing in research and development, Sight Sciences aims to push the boundaries of ophthalmology and optometry, introducing solutions that can significantly improve quality of life. Their mission is to provide cutting-edge treatments that offer more effective and safer alternatives to traditional surgical procedures. As a single-listed entity, Sight Sciences leverages its position on NASDAQ:SGHT to further its research endeavors, expand its market reach, and continue its commitment to advancing ocular health worldwide through innovation and collaboration.

Resumo

Public USParticipação acionária
2010Ano de fundação
214Funcionários
Menlo Park, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
Edison, US

Produtos e/ou serviços de Sight Sciences

  • OMNI Surgical System, a minimally invasive glaucoma surgery device designed to reduce intraocular pressure by enhancing aqueous outflow.
  • TearCare System, a wearable eyelid technology for managing evaporative dry eye disease by applying controlled heat to the eyelids.
  • VISCO360 Viscosurgical System for minimally invasive glaucoma surgeries, facilitating increased aqueous outflow to lower intraocular pressure.
  • SION Surgical System, offering advanced technology for precision in minimally invasive glaucoma surgeries.
  • Handheld surgical instruments tailored for ophthalmic procedures, enhancing efficiency and outcomes in eye surgeries.
  • Research and development in innovative devices and technologies aimed at addressing the unmet needs in ocular diseases.

equipe executiva do Sight Sciences

  • Paul BadawiCo-Founder, President, CEO & Director
  • Alison Perry BauerleinChief Operating Officer
  • David BadawiCo-Founder, CTO & Director
  • James RodbergCFO & Treasurer
  • Steve R. Tamayo Jr.VP and Chief Ethics & Compliance Officer
  • Kashif RashidChief Legal Officer & Corporate Secretary
  • Kelly VaupelVice President of Marketing & Commercial Strategy, Interventional Glaucoma
  • Sonia ClarkVice President of People
  • Brenton TaylorExecutive Vice President of Operations and R&D
  • Kelly PetrucciSenior Vice President of Market Access & Strategy

Principais indicadores financeiros

Resultados divulgados pela Sight Sciences, em USD.

Cap. de mercado
497,4 mi
Receita (TTM)
83,4 mi
P/L
—
LPA (diluído, TTM)
-0.6
Dividend yield
—
Margem de lucro
-35.7%
Receita e lucro anuais da Sight Sciences
Fim do ano fiscalReceitaResultado operacionalLucro líquido
77,4 mi-37,1 mi-38,4 mi
79,9 mi-50,5 mi-51,5 mi
81,1 mi-57,3 mi-55,5 mi
71,3 mi-84 mi-86,2 mi